Production Of Human Growth Hormone Research Articles

The automated production by immunoaffinity chromatography of the human pituitary glycoprotein hormones thyrotropin, follitropin and lutropin

AbstractHuman pituitary TSH, FSH and LH were purified from a side fraction of human pituitary growth hormone production by immunoaffinity chromatography on immobilised hormone‐specific monoclonal antibodies. Each hormone was obtained in biologically active form and was substantially free, <0·5% by weight, of the other glycoprotein hormones. The method was automated using a time‐based programmer and by applying the unbound fraction from one purification to columns of different specificities each of the three hormones was obtained from a single batch of starting material.

The purification of human thyroid‐stimulating hormone by immunoaffinity chromatography

AbstractHuman thyrotropin (thyroid‐stimulating hormone) has been purified from a side‐fraction of human growth hormone production. Purification is effected by immunoaffinity chromatography on an immobilised monoclonal antibody column. The hormone was bound to the immunoabsorbent in 50 mM borate buffer pH 8·5 plus 0·5 M NaCl and eluted by 50 mM glycine/HCl buffer pH 3·5 plus 0·5 M NaCl. The hormone was obtained in a biologically active form and substantially free, <0·5% by weight, of the other pituitary glycoprotein hormones.

Monitoring the production of biosynthetic human growth hormone by micro enzyme-linked immunosorbent assay

A micro enzyme-linked immunosorbent assay (e.l.i.s.a.) has been developed for monitoring the production of human growth hormone (hGH) in E. coli. The method is unusually flexible, as it is possible to modify its conditions to give a sensitive (detection limit 4 ng l −1) or a fast (6 h) version. The assay is reproducible; the between-assay relative standard deviation is 6%. The effects of temperature, incubation time and the concentrations of protein and the most important reagents (the solid-phase antibody and the labelled antibody) are described. The utility of the method is demonstrated in experiments optimizing the conditions for production of hGH in E. coli.

Efficacy and pharmacokinetics of recombinant DNA derived human growth hormone in rats and monkeys

Production of human growth hormone by bacteria harboring a plasmid gene increases the potential availability of the hormone for human clinical use. The efficacy of this material has been determined by growth promoting effects in rats and clinical chemistry parameters in rats and monkeys. Comparison of the pharmacokinetics of the hormone administered intramuscularly or sub-cutaneously indicates that essentially similar effects are achieved. Other biochemical properties also indicate that the sub-cutaneous route is not associated with potential adverse effects, supporting use of the material for a variety of clinical indications.

Teams vie in synthetic production of human growth hormone

Teams vie in synthetic production of human growth hormone

Teams vie in synthetic production of human growth hormone

Hypopituitary children throughout the world soon may have a better chance for normal growth, thanks to the synthesis of human somatotropin or growth hormone (HGH) by two groups of genetic engineers. Almost simultaneously, the two groups—one headed by John D. Baxter, MD, and Howard Goodman, MD, at the University of California-San Francisco's Howard Hughes Medical Institute, and the other directed by senior scientists David Goeddel, PhD, and Peter Seeburg, PhD, at Genentech, Inc, in South San Francisco—announced that they had produced HGH in bacterial cells using recombinant DNA technology. Each group believes its achievement is unique. The Genentech group used synthetic DNA fragments provided by Keiichi Itakura, PhD, and associates of the City of Hope National Medical Center, Duarte, Calif. They joined the fragments enzymatically, forming a single DNA segment that contained the genetic code for approximately 12% of the HGH polypeptide. Subsequently, they converted messenger RNA for HGH (extracted

Measurement of human growth hormone production rate recommendations for a standardized protocol

The kinetic of human growth hormone (HGH) have been investigated as a function of experimental duration. Using a 2 compartmental model, significant changes in the production rate was observed when the duration of experiment was changed. On the basis of statistical criteria, a time of 4 hr is recommended as the optimum duration of the study.

Growth hormone secreting carcinoma of lung and hypertrophic osteoarthropathy.

Plasma Human Growth Hormone (HGH) was raised in a patient with bronchial carcinoma and hypertrophic pulmonary osteoarthropathy before radiotherapy to the tumour. Though the soft-tissue swelling and pain of hypertrophic osteoarthropathy disappeared two to three weeks after radiotherapy to the carcinoma the HGH plasma levels were still very high at two months and came back to normal levels at six months and remained so at one year. It is suggested that ectopic production of HGH by the tumour in this case was not responsible for the changes of hypertrophic osterarthropathy.

Daily production and metabolic clearance of growth hormone in juvenile diabetes mellitus.

Daily production (PR) of human growth hormone (HGH) was calculated in patients with juvenile diabetes and control subjects by determining metabolic clearance rate (MCR) of131I HGH, at equilibrium, and mean endogenous HGH levels throughout a 24 h day. Half hourly sampling or a constant withdrawal pump were used to obtain an integrated mean endogenous HGH level. MCR (liters/day) was significantly reduced in all diabetic subjects both in absolute terms (96 ± 15 vs 274 ± 37) and relative to surface area (62 ± 8 vs 171 ± 21) (p < 0.01). Mean HGH levels were 8.4 ng/ml in the diabetics and 5.5 ng/ml in age matched controls. Daily HGH PR in the diabetic subjects (339 to 1365 μg/day) did not exceed values in the control subjects (1005–1426 μg/day). The results indicate that the elevated plasma HGH levels and increased HGH response to stimuli observed in diabetes, reflect reduced metabolic clearance, rather than increased pituitary secretion.

Cortisol stimulation of growth hormone production by human pituitary tissue in culture.

ABSTRACT Human growth hormone (HGH) production increased as much as 30-fold after the addition of 5×10−6 to 5×10−7m cortisol to explant cultures of pituitary adenomas from acromegalic patients. Increases in HGH production were also noted in 2 of 4 cultures of normal human pituitaries. This study extends to the human the previously described stimulatory action of cortisol on growth hormone production in cultures of normal monkey and rat pituitary tumor cells.